Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Sota, Jurgen; Breda, Luciana; Paroli, Maria; Hashad, Soad; de-la-Torre, Alejandra; Guerriero, Silvana; TUFAN, ABDURRAHMAN; Cardona-Lopez, Juanita; Altamar-Garcia, Maria; La Bella, Saverio; Vitale, Antonio; Biancalana, Edoardo; Del Giudice, Emanuela; Minoia, Francesca; Al-Mayouf, Sulaiman; Frediani, Bruno; Cantarini, Luca; Fabiani, Claudia

doi:10.1136/bjo-2025-327410

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Sota J., Breda L., Paroli M. P., Hashad S., de-la-Torre A., Guerriero S., ...Daha Fazla

BRITISH JOURNAL OF OPHTHALMOLOGY, cilt.109, sa.10, ss.1151-1154, 2025 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Editöre Mektup
Cilt numarası: 109 Sayı: 10
Basım Tarihi: 2025
Doi Numarası: 10.1136/bjo-2025-327410
Dergi Adı: BRITISH JOURNAL OF OPHTHALMOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
Sayfa Sayıları: ss.1151-1154
Gazi Üniversitesi Adresli: Evet

Özet

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.